Outcome of the Board meeting held on 15.01.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Godavari Drugs Ltd, at its meeting on 15 January 2026, approved raising funds through a preferential issue on two fronts. First, up to 23,60,065 convertible warrants will be issued to promoters at Rs. 89 per warrant, with each warrant convertible into one equity share of Rs. 10 face value within 18 months. Second, up to 25,96,935 equity shares will be issued to promoters and non-promoters at Rs. 89 per share, with 31 allottees including individuals, LLPs, and small funds. Together, the two issues could raise roughly Rs. 44 crore (23,60,065 + 25,96,935 securities at Rs. 89 each). Post-allotment, promoter holding is projected at 51.52% and public at 48.48%. An Extra Ordinary General Meeting has been scheduled for 12 February 2026 to seek shareholder approval.
This is a promoter-led capital infusion that keeps promoter shareholding just above the 51% majority threshold, avoiding any potential open offer trigger. The Rs. 89 issue price is fixed and well above the Rs. 10 face value, but the stock could face short-term dilution pressure once the shares and warrants are allotted and converted.